PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.

Since 2010, significant progress has been made in the treatment of metastatic castrate resistant prostate cancer (mCRPC). While these advancements have improved survival, mCRPC remains a lethal disease, with a precision medicine framework that is lagging behind compared to other cancers. Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) studies in prostate cancer (PCa) have focused primarily on the homologous recombination repair (HRR) genes, specifically BRCA1 and BRCA2.

Pathogenic Variants as Biomarkers for Risk in Prostate Cancer.

Studies have demonstrated that men with Prostate Cancer (PCa) harboring genetic aberrations, are more likely to have worse disease and a poorer prognosis. A mutation in is known to confer the highest risk of PCa for men (8.6 fold in men ≤65 years) making genes a conceivable genomic biomarker for risk in PCa.

Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics.

Advanced diagnostics are enabling cancer treatments to become increasingly tailored to the individual through developments in immunotherapies and targeted therapies. However, long turnaround times and high costs of molecular testing hinder the widespread implementation of targeted cancer treatments. Meanwhile, gold-standard histopathological assessment carried out by a trained pathologist is widely regarded as routine and mandatory in most cancers.

Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer.

Prostate Cancer (PCa) is a leading cause of morbidity and mortality among men worldwide. For most men with PCa, their disease will follow an indolent course. However, advanced PCa is associated with poor outcomes.